Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?

Primary Journalistic Dispatch & Direct Reporting

Amgen (AMGN) yields 2.6% with a $10.08 annualized payout, topping Merck (MRK) at 2.29%, and has raised its dividend 6% annually versus Merck's smaller step-ups.

Amgen's 17 billion-dollar products and $3.5B quarterly free cash flow dwarf Merck's reliance on a single Keytruda franchise facing peak penetration.

Merck absorbed a $5.7B acquisition charge that pushed Q2 earnings to a loss, while Amgen raised 2026 EPS guidance to as high as $23.50.

In-Depth Developments & Factual Context

Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut. Enter your email to see the names that beat MRK. The report is free. Enter your email and see if any of your stocks made the cut.

For a retirement portfolio that leans on pharma dividends, the choice between Amgen ( NASDAQ:AMGN ) and Merck ( NYSE:MRK ) comes down to one question: which check is more likely to keep getting bigger through the next wave of patent expirations? Both companies deliver quarterly income today. Only one has the coverage, the growth cadence, and the portfolio breadth to keep raising through the cliff.

Amgen pays a quarterly dividend of $2.52 per share, an annualized forward payout of $10.08. At $385.28, that lands at a yield of roughly 2.6%. Merck pays $0.85 quarterly, or $3.40 annualized, and at $146.65 yields 2.29%.

Industry Impact & Strategic Analysis

On starting yield, Amgen wins. It is not a wide gap, but for a retiree sizing positions to hit an income target, the difference compounds. An investor putting $100,000 to work today gets meaningfully more current cash from AMGN, and the gap holds even after Merck's 85.17% one-year rally compressed its yield. Winner: Amgen.

Both boards raise annually, and both raised again this year. The verified quarterly progression tells the story.

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now . Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

Forward Outlook & Market Perspective

The report is free, and you can see why we think each stock is a top investment today.

Amgen: $2.13 (2023) to $2.25 (2024) to $2.38 (2025) to $2.52 (2026). Management characterized the latest hike as a 6% increase, matching the pace of the prior year's raise.

Merck: $0.73 (2023) to $0.77 (2024) to $0.81 (2025) to $0.85 (2026). The 2026 hike from $0.81 to $0.85 is a smaller step in dollar terms and in percentage terms than Amgen's.

Amgen has been pushing 6% raises consistently while Merck's step-ups have been closer to the mid-single-digit range with a smaller relative bump this cycle. For an income holder who needs the payout to outrun inflation, Amgen's steeper trajectory matters more than Merck's slightly larger share count leverage. Winner: Amgen.

This is where the matchup is decided. Merck's Keytruda franchise generated $8.4 billion in Q2 2026 sales, and the CFO warned that "total U.S. Keytruda year-over-year growth will moderate as we increasingly reach peak penetration." The company's answer is a $70 billion commercial opportunity across more than 20 new products, with the CEO framing loss of exclusivity as "more of a hill than a cliff." That is a bet on pipeline execution, and the Q2 quarter absorbed a $5.7 billion charge tied to the Terns acquisition, pushing GAAP earnings to a $0.13 per share loss.

Amgen's income base is broader by design. In Q2 2026 the company reported $3.5 billion in free cash flow, 22 products with double-digit growth, and 17 products annualizing above $1 billion. Six growth drivers, Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimilars, grew 26% collectively and now represent nearly 70% of product sales. Biosimilar erosion is already visible in Prolia and Xgeva, down 33% together, and the dividend kept rising through it.

Reporting synthesized and verified under Nexvoro.tech editorial guidelines. Full primary records referenced via Yahoo Finance.